CYTK Cytokinetics
- 65.390
- +1.050+1.63%
Cytokinetics News
Express News | Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
(CYTK) - Analyzing Cytokinetics's Short Interest
Cytokinetics's (NYSE:CYTK) short percent of float has fallen 11.8% since its last report. The company recently reported that it has 13.23 million shares sold short, which is 20.7% of all regular share
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV), Molina Healthcare (MOH) and Cytokinetics (CYTK)
Unusual Options Activity: STE, VST and Others Attract Market Bets, STE V/OI Ratio Reaches 107.7
EST Apr 29th Closing Delivery - In the last three hours of trading, 10 options with a high V/OI ratio were detected. With the market volatile, it's crucial to stay informed on the latest options trend
Cytokinetics to Host Investor Event and Conference Call to Discuss the Primary Results From SEQUOIA-HCM at the European Society of Cardiology Heart Failure 2024 Congress
SOUTH SAN FRANCISCO, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced it will host an investor event and conference call on May 13, 2024 at 4:00 PM Western European
Cytokinetics Appoints Sung H. Lee as New CFO
Express News | Cytokinetics - on April 23, Entered Employment Offer Letter With Sung H. Lee, Pursuant to Which, Lee Agreed to Serve as Executive Vice President, CFO
Cytokinetics(CYTK.US) Director Sells US$681.67K in Common Stock
$Cytokinetics(CYTK.US)$ Director HENDERSON JOHN T sold 10,562 shares of common stock on Apr 25, 2024 at an average price of $64.54 for a total value of $681.67K.Source: Announcement What is statement
Form 144 | Cytokinetics(CYTK.US) Director Proposes to Sell 681.63K in Common Stocks
SEC FILLINGS DISCLOSED/ Apr 25, $Cytokinetics(CYTK.US)$ Director JOHN T HENDERSON intends to sell 10,562 shares of its common stock on Apr 25, with a total market value of approximately $681.63K. JO
Express News | Cytokinetics to Announce First Quarter Results on May 8, 2024
Analysts' Top Healthcare Picks: Cytokinetics (CYTK), Ultragenyx Pharmaceutical (RARE)
This Weight-loss ETF Has Performed Well in Its First Five Months. How Does It Compare With Cheaper Alternatives?
Cytokinetics Announces Three Late Breaking Clinical Trial Presentations Relating to SEQUOIA-HCM at the European Society of Cardiology Heart Failure 2024 Congress
Cytokinetics, Incorporated (Nasdaq: CYTK) today announced three Late Breaking Clinical Trial presentations relating to SEQUOIA-HCM.
EVP Research & Development Fady Malik Sells Shares of Cytokinetics Inc (CYTK)
Cytokinetics(CYTK.US) Officer Sells US$2.42 Million in Common Stock
$Cytokinetics(CYTK.US)$ Officer Malik Fady Ibraham sold 32,605 shares of common stock on Apr 9, 2024 at an average price of $74.31 for a total value of $2.42 million.Source: Announcement What is state
Cytokinetics Insider Sold Shares Worth $2,422,918, According to a Recent SEC Filing
Fady Ibraham Malik, Executive Vice President, Research & Development, on April 09, 2024, sold 32,605 shares in Cytokinetics (CYTK) for $2,422,918. Following the Form 4 filing with the SEC, Malik has c
Form 144 | Cytokinetics(CYTK.US) Officer Proposes to Sell 2.42 Million in Common Stocks
SEC FILLINGS DISCLOSED/ Apr 9, $Cytokinetics(CYTK.US)$ Officer FADY MALIK intends to sell 32,605 shares of its common stock on Apr 9, with a total market value of approximately $2.42 million. FADY M
Express News | Needham Reiterates Buy on Cytokinetics, Maintains $108 Price Target
Express News | Truist Securities Reiterates Buy on Cytokinetics, Maintains $86 Price Target
Cytokinetics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/08/2024 17.05% Truist Securities $86 → $86 Reiterates Buy → Buy 03/07/2024 4.8% JP Morgan $78 → $77 Mai
Analysis
Price Target
No Data
